168 related articles for article (PubMed ID: 38397996)
21. Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia is predictive for relapse.
Reif SW; Wiesner D; Duell T; Mittermueller J; Schmetzer HM
Eur J Haematol; 2001 Oct; 67(4):207-20. PubMed ID: 11860441
[TBL] [Abstract][Full Text] [Related]
22. [Establishment of a patient-derived xenograft humanized mouse model for hepatoblastoma in children].
Hu HM; Zhang WL; Huang DS; Li R; Gu HL; Li J; Gao YN
Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1075-1080. PubMed ID: 38016773
[No Abstract] [Full Text] [Related]
23. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
Marques Da Costa ME; Zaidi S; Scoazec JY; Droit R; Lim WC; Marchais A; Salmon J; Cherkaoui S; Morscher RJ; Laurent A; Malinge S; Mercher T; Tabone-Eglinger S; Goddard I; Pflumio F; Calvo J; Redini F; Entz-Werlé N; Soriano A; Villanueva A; Cairo S; Chastagner P; Moro M; Owens C; Casanova M; Hladun-Alvaro R; Berlanga P; Daudigeos-Dubus E; Dessen P; Zitvogel L; Lacroix L; Pierron G; Delattre O; Schleiermacher G; Surdez D; Geoerger B
Commun Biol; 2023 Sep; 6(1):949. PubMed ID: 37723198
[TBL] [Abstract][Full Text] [Related]
24. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
25. Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ
J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
[TBL] [Abstract][Full Text] [Related]
26. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.
Wang K; Sanchez-Martin M; Wang X; Knapp KM; Koche R; Vu L; Nahas MK; He J; Hadler M; Stein EM; Tallman MS; Donahue AL; Frampton GM; Lipson D; Roels S; Stephens PJ; Sanford EM; Brennan T; Otto GA; Yelensky R; Miller VA; Kharas MG; Levine RL; Ferrando A; Armstrong SA; Krivtsov AV
Leukemia; 2017 Jan; 31(1):151-158. PubMed ID: 27363283
[TBL] [Abstract][Full Text] [Related]
27. Engraftment characterization of risk-stratified AML in NSGS mice.
Díaz de la Guardia R; Velasco-Hernandez T; Gutiérrez-Agüera F; Roca-Ho H; Molina O; Nombela-Arrieta C; Bataller A; Fuster JL; Anguita E; Vives S; Zamora L; Nomdedeu J; Gómez-Casares MT; Ramírez-Orellana M; Lapillonne H; Ramos-Mejia V; Rodríguez-Manzaneque JC; Bueno C; Lopez-Millan B; Menéndez P
Blood Adv; 2021 Dec; 5(23):4842-4854. PubMed ID: 34470043
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line.
Cheung PF; Yip CW; Ng LW; Lo KW; Chow C; Chan KF; Cheung TT; Cheung ST
Cancer Cell Int; 2016; 16():41. PubMed ID: 27279800
[TBL] [Abstract][Full Text] [Related]
29. Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo.
Bahrami E; Schmid JP; Jurinovic V; Becker M; Wirth AK; Ludwig R; Kreissig S; Duque Angel TV; Amend D; Hunt K; Öllinger R; Rad R; Frenz JM; Solovey M; Ziemann F; Mann M; Vick B; Wichmann C; Herold T; Jayavelu AK; Jeremias I
Mol Cancer; 2023 Jul; 22(1):107. PubMed ID: 37422628
[TBL] [Abstract][Full Text] [Related]
30. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.
Scott CL; Becker MA; Haluska P; Samimi G
Front Oncol; 2013 Dec; 3():295. PubMed ID: 24363999
[TBL] [Abstract][Full Text] [Related]
31. Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
Villanueva H; Wells GA; Miller MT; Villanueva M; Pathak R; Castro P; Ittmann MM; Sikora AG; Lerner SP
Heliyon; 2022 Dec; 8(12):e12570. PubMed ID: 36643309
[TBL] [Abstract][Full Text] [Related]
32. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.
Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H
Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849
[TBL] [Abstract][Full Text] [Related]
34. Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts).
Hernández Guerrero T; Baños N; Del Puerto Nevado L; Mahillo-Fernandez I; Doger De-Speville B; Calvo E; Wick M; García-Foncillas J; Moreno V
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001663
[No Abstract] [Full Text] [Related]
35. PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.
Yang J; Li Q; Noureen N; Fang Y; Kurmasheva R; Houghton PJ; Wang X; Zheng S
Nucleic Acids Res; 2021 Jan; 49(D1):D1321-D1327. PubMed ID: 32810235
[TBL] [Abstract][Full Text] [Related]
36. Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines.
Woo XY; Srivastava A; Graber JH; Yadav V; Sarsani VK; Simons A; Beane G; Grubb S; Ananda G; Liu R; Stafford G; Chuang JH; Airhart SD; Karuturi RKM; George J; Bult CJ
BMC Med Genomics; 2019 Jul; 12(1):92. PubMed ID: 31262303
[TBL] [Abstract][Full Text] [Related]
37. Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for
Brock RM; Beitel-White N; Coutermarsh-Ott S; Grider DJ; Lorenzo MF; Ringel-Scaia VM; Manuchehrabadi N; Martin RCG; Davalos RV; Allen IC
Front Oncol; 2020; 10():843. PubMed ID: 32528898
[TBL] [Abstract][Full Text] [Related]
38. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors.
Koga Y; Ochiai A
Cells; 2019 May; 8(5):. PubMed ID: 31064068
[TBL] [Abstract][Full Text] [Related]
39. Patient-derived xenograft (PDX) models: characteristics and points to consider for the process of establishment.
Fujii E; Kato A; Suzuki M
J Toxicol Pathol; 2020 Jul; 33(3):153-160. PubMed ID: 32764840
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
